Trial Outcomes & Findings for The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function (NCT NCT03115853)

NCT ID: NCT03115853

Last Updated: 2017-08-25

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

31 participants

Primary outcome timeframe

baseline to 18 weeks

Results posted on

2017-08-25

Participant Flow

The data for this study was lost. The total number of participants enrolled/completed was pulled from IRB records. Participant age was between 18-65 per protocol. All participants were enrolled in the United States. No other data is available.

Participant milestones

Participant milestones
Measure	All Participants all participants enrolled in the study
Overall Study STARTED	31
Overall Study COMPLETED	31
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	All Participants n=31 Participants
Age, Categorical <=18 years	0 Participants n=31 Participants
Age, Categorical Between 18 and 65 years	31 Participants n=31 Participants
Age, Categorical >=65 years	0 Participants n=31 Participants
Region of Enrollment United States	31 participants n=31 Participants

PRIMARY outcome

Timeframe: baseline to 18 weeks

Population: data was lost and results are unknown

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: baseline to 18 weeks

Population: data was lost and results are unknown

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: baseline to 18 weeks

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: baseline to 18 weeks

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: baseline to 18 weeks

Population: data was lost and results are unknown

Outcome measures

Outcome data not reported

Adverse Events

All Participants

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

James Muldowney, MD

Vanderbilt University Medical Center

Phone: 615-936-1720

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place